Zymeworks (ZYME) Competitors

$24.43 +0.50 (+2.09%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$24.64 +0.21 (+0.86%)

As of 06:12 AM Eastern

ZYME vs. PCVX, KYMR, QGEN, RYTM, and TGTX

Should you buy Zymeworks stock or one of its competitors? MarketBeat compares Zymeworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zymeworks include Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Qiagen (QGEN), Rhythm Pharmaceuticals (RYTM), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Zymeworks compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vaxcyte has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Vaxcyte's return on equity of -32.51% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Zymeworks	-126.92%	-37.97%	-25.31%

Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 77.54%. Zymeworks has a consensus price target of $38.00, indicating a potential upside of 55.55%. Given Vaxcyte's higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Zymeworks had 14 more articles in the media than Vaxcyte. MarketBeat recorded 19 mentions for Zymeworks and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.70 beat Zymeworks' score of 0.60 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Zymeworks has higher revenue and earnings than Vaxcyte. Zymeworks is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Zymeworks	$105.96M	16.84	-$81.13M	-$1.37	N/A

Summary

Zymeworks beats Vaxcyte on 9 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Zymeworks has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	167.14	-$311.35M	-$3.57	N/A
Zymeworks	$105.96M	16.84	-$81.13M	-$1.37	N/A

In the previous week, Zymeworks had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 19 mentions for Zymeworks and 7 mentions for Kymera Therapeutics. Zymeworks' average media sentiment score of 0.60 beat Kymera Therapeutics' score of 0.30 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Zymeworks shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kymera Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Kymera Therapeutics currently has a consensus price target of $118.10, indicating a potential upside of 48.23%. Zymeworks has a consensus price target of $38.00, indicating a potential upside of 55.55%. Given Zymeworks' higher probable upside, analysts plainly believe Zymeworks is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Zymeworks has a net margin of -126.92% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Zymeworks	-126.92%	-37.97%	-25.31%

Summary

Zymeworks beats Kymera Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Zymeworks compare to Qiagen?

Qiagen (NYSE:QGEN) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Qiagen has a net margin of 19.16% compared to Zymeworks' net margin of -126.92%. Qiagen's return on equity of 14.40% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Zymeworks	-126.92%	-37.97%	-25.31%

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Zymeworks had 10 more articles in the media than Qiagen. MarketBeat recorded 19 mentions for Zymeworks and 9 mentions for Qiagen. Zymeworks' average media sentiment score of 0.60 beat Qiagen's score of 0.36 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen currently has a consensus price target of $44.98, suggesting a potential upside of 33.17%. Zymeworks has a consensus price target of $38.00, suggesting a potential upside of 55.55%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Qiagen has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.33	$424.88M	$1.91	17.68
Zymeworks	$105.96M	16.84	-$81.13M	-$1.37	N/A

Summary

Zymeworks beats Qiagen on 10 of the 17 factors compared between the two stocks.

How does Zymeworks compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Zymeworks has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.36	-$196.54M	-$3.13	N/A
Zymeworks	$105.96M	16.84	-$81.13M	-$1.37	N/A

Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Zymeworks has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus target price of $131.81, suggesting a potential upside of 51.79%. Zymeworks has a consensus target price of $38.00, suggesting a potential upside of 55.55%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Zymeworks	-126.92%	-37.97%	-25.31%

In the previous week, Zymeworks had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Zymeworks and 14 mentions for Rhythm Pharmaceuticals. Zymeworks' average media sentiment score of 0.60 beat Rhythm Pharmaceuticals' score of -0.31 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Zymeworks shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zymeworks beats Rhythm Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Zymeworks compare to TG Therapeutics?

Zymeworks (NASDAQ:ZYME) and TG Therapeutics (NASDAQ:TGTX) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Zymeworks has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Zymeworks presently has a consensus price target of $38.00, indicating a potential upside of 55.55%. TG Therapeutics has a consensus price target of $52.50, indicating a potential upside of 32.98%. Given Zymeworks' stronger consensus rating and higher possible upside, equities analysts plainly believe Zymeworks is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

TG Therapeutics has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.84	-$81.13M	-$1.37	N/A
TG Therapeutics	$616.29M	9.81	$447.18M	$2.86	13.80

TG Therapeutics has a net margin of 65.95% compared to Zymeworks' net margin of -126.92%. TG Therapeutics' return on equity of 88.73% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
TG Therapeutics	65.95%	88.73%	43.44%

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Zymeworks had 17 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for Zymeworks and 2 mentions for TG Therapeutics. Zymeworks' average media sentiment score of 0.60 beat TG Therapeutics' score of 0.30 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zymeworks beats TG Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.75B	$916.90M	$4.17B	$12.29B
Dividend Yield	N/A	4.84%	6.12%	5.30%
P/E Ratio	-17.83	1.49	22.73	25.23
Price / Sales	16.84	113.63	118.57	79.80
Price / Cash	N/A	20.07	50.53	37.30
Price / Book	6.81	8.47	38.49	6.63
Net Income	-$81.13M	-$3.49M	$113.56M	$335.59M
7 Day Performance	2.22%	7.48%	1.01%	-1.20%
1 Month Performance	-12.12%	78.28%	1.18%	-1.16%
1 Year Performance	N/A	139.69%	14.39%	28.10%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	3.2607 of 5 stars	$24.43 +2.1%	$38.00 +55.5%	N/A	$1.75B	$105.96M	N/A	460	Buyback Announcement
PCVX Vaxcyte	2.8714 of 5 stars	$53.01 +3.0%	$86.00 +62.2%	+52.1%	$7.43B	N/A	N/A	160
KYMR Kymera Therapeutics	2.2137 of 5 stars	$86.08 +1.7%	$118.10 +37.2%	+163.4%	$6.96B	$39.21M	N/A	170
QGEN Qiagen	4.576 of 5 stars	$33.05 -1.4%	$46.38 +40.3%	-24.8%	$6.91B	$2.09B	17.26	5,654	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.2913 of 5 stars	$94.17 -2.1%	$131.81 +40.0%	+44.9%	$6.59B	$189.76M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. PCVX, KYMR, QGEN, RYTM, and TGTX

How does Zymeworks compare to Vaxcyte?

Summary

How does Zymeworks compare to Kymera Therapeutics?

Summary

How does Zymeworks compare to Qiagen?

Summary

How does Zymeworks compare to Rhythm Pharmaceuticals?

Summary

How does Zymeworks compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. PCVX, KYMR, QGEN, RYTM, and TGTX

How does Zymeworks compare to Vaxcyte?

Do insiders & institutionals have more ownership in PCVX or ZYME?

Is PCVX or ZYME more profitable?

Do analysts recommend PCVX or ZYME?

Does the media favor PCVX or ZYME?

Which has more volatility & risk, PCVX or ZYME?

Which has preferable valuation & earnings, PCVX or ZYME?

Summary

How does Zymeworks compare to Kymera Therapeutics?

Which has better valuation and earnings, KYMR or ZYME?

Does the media favor KYMR or ZYME?

Do institutionals & insiders have more ownership in KYMR or ZYME?

Which has more risk & volatility, KYMR or ZYME?

Do analysts prefer KYMR or ZYME?

Is KYMR or ZYME more profitable?

Summary

How does Zymeworks compare to Qiagen?

Is QGEN or ZYME more profitable?

Do institutionals and insiders hold more shares of QGEN or ZYME?

Which has more risk and volatility, QGEN or ZYME?

Does the media refer more to QGEN or ZYME?

Do analysts prefer QGEN or ZYME?

Which has higher valuation and earnings, QGEN or ZYME?

Summary

How does Zymeworks compare to Rhythm Pharmaceuticals?

Which has preferable earnings and valuation, RYTM or ZYME?

Which has more volatility & risk, RYTM or ZYME?

Do analysts recommend RYTM or ZYME?

Is RYTM or ZYME more profitable?

Does the media favor RYTM or ZYME?

Do institutionals & insiders hold more shares of RYTM or ZYME?

Summary

How does Zymeworks compare to TG Therapeutics?

Which has more volatility and risk, ZYME or TGTX?

Do analysts recommend ZYME or TGTX?

Which has higher earnings and valuation, ZYME or TGTX?

Is ZYME or TGTX more profitable?

Do institutionals and insiders have more ownership in ZYME or TGTX?

Does the media prefer ZYME or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools